The emerging market dynamics of targeted therapeutics

Health Affairs

Volumn 25, Issue 5, 2006, Pages 1302-1308

  Calfee, John E ^a   DuPré, Elizabeth ^b  

^a AMERICAN ENTERPRISE INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; ECONOMICS; GENE TARGETING; HUMAN; REVIEW; UNITED STATES;

BIOTECHNOLOGY; DRUG COSTS; DRUG DELIVERY SYSTEMS; DRUG INDUSTRY; GENE TARGETING; HUMANS; UNITED STATES;

EID: 33749357202     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.25.5.1302     Document Type: Review

References (26)

1. A. Berenson, "A Cancer Drug Shows Promise, at a Price That Many Can't Pay," New York Times, 15 February 2006;
2. J. Carreyrou and G. Anand, "Wary of Backlash, Cancer-Drug Makers Weigh Price Limits," Wall Street Journal, 10 May 2006:
3. S.D. Pearson and M.D. Rawlins, "Quality, Innovation, and Value for Money: NICE and the British National Health Service," Journal of the American Medical Association 294, no. 20 (2005): 2618-2622;
4. "NHS Rationing Must Be Scrutinized" (editorial), Guardian(U.K.), 14 August 2005;
5. and N. Hawkes, "Delay over Top Cancer Treatment for Women," London Times, 29 December 2005.
6. A good discussion of the diffuse concepts of biotechnology and biotech drugs is R.A. Rader, "What Is a Biopharmaceutical? Part 1: (Bio)Technology-based Definitions," BioExecutive International (March 2005): 60-65.
7. A. Pollack, "Questions over New Eyesight Drug That May Be as Good as Older, Cheaper One," New York Times, 29 June 2006.
8. "One Drug, Multiple Treatments," Washington Post, 1March 2006.
9. Essential sources are S. Usdin, "Countdown to Biogenerics," BioCentury 10, no. 17 (2002): A1-A8;
10. S. Usdin, "FOBs on the Ground," BioCentury 13, no. 53 (2005): A16-A17;
11. and B.S. Manheim Jr., P. Granahan, and K.J. Dow, "'Follow-On Biologics:' Ensuring Continued Innovation in the Biotechnology Industry," Health Affairs 25, no. 2 (2006): 394-404.
12. J.E. Calfee, M. Villarreal, and E. DuPré, "An Exploratory Analysis of Pharmaceutical Price Disparities and Their Implications among Six Developed Nations," Working Paper no. 06-07, April 2006, http://www.aei.brookings.org/admin/authorpdfs/page.php?id=1265. (accessed 8 June 2006).
13. J.E. Calfee, "The Vioxx Fallout," American Enterprise Institute Health Policy Outlook, September-October 2005, http://www.aei.org/publications/ pubID.23275,filter.all/pub_detail.asp (accessed 8 June 2006).
14. J. Marx, "Cancer: Encouraging Results for Second-Generation Antiangiogenesis Drugs," Science 308, no. 5726 (2005): 1248-1249;
15. and K. Bernstein, "Targeted ≠ Narrow," BioCentury 14, no. 10 (2006): A1-A9.
16. Berenson, "A Cancer Drug Shows Promise."
17. E. Waltz, "GlaxoSmithKline Cancer Drug Threatens Herceptin Market," Nature Biotechnology 23, no. 12 (2005): 1453-1454.
18. T. Hampton, "Looking beyond Imatinib: Next Line of Targeted Drugs for CML Shows Promise," Journal of the American Medical Association 295, no. 4 (2006): 369-370.
19. Bernstein, "Targeted ≠ Narrow."
20. M. Flanagan, "Avastin's Progression," BioCentury 14, no. 11 (2006): A1-A5.
21. Bernstein, "Targeted ≠ Narrow";
22. Hampton, "Looking beyond Imatinib"; and "Bristol-Myers Gets FDA Approval for Leukemia Drug," Wall Street Journal, 29 June 2006.
23. L. Wess, "Building on Safe Ground," BioCentury 12, no. 42 (2004): A1-A20.
24. S. Usdin, "Starting Down the Path," BioCentury 13, no. 50 (2005): A1-A5.
25. T.G. Roberts Jr., T.J. Lynch Jr., and B.A. Chabner, "The Phase III Trial in the Era of Targeted Therapy: Unraveling the 'Go or No Go' Decision," Journal of Clinical Oncology 21, no. 19 (2003): 3683-3695.
26. Usdin, "Starting Down the Path."